D. Samba Reddy, Ph.D., R.Ph.
8447 State Highway 47
2008 Medical Research and Education Building
Bryan, TX 77807-3260
- Ph.D., Pharmacology, Panjab University Chandigarh (1998)
- R.Ph, Pharmacy, Texas State BOP, Austin, Texas.
- Postdoctoral Fellow, National Institutes of Health, Bethesda, Maryland.
- Fellow, American Epilepsy Society (AES)
- Fellow, American Association for the Advancement of Science (AAAS)
- Fellow, American Association of Pharmaceutical Scientists (FAAPS)
- SAB Member, Environmental Protection Agency (EPA)
- Contributing Editor, Epilepsy Currents
- Chartered Member, NIH Study Section CNNT - Clinical Neuroplasticity and Neurotransmitters
- Editor-in-Chief, International Journal of Pharmaceutical Sciences and Nanotechnology
- Review Editor, Frontiers in Neuroscience & Frontiers in Pharmacology
- Delegate Member, The United States Pharmacopoeia (USP)
- Registered Pharmacy Practitioner, Texas, United States
Translational Pharmacology and Neurotherapeutics of Epilepsy and Brain Disorders
Dr. Reddy has been in the pharmacology research field for over 23 years. His lab is mainly focused on drug development for epilepsy and brain disorders. Epilepsy and seizure disorders affect about 50 million people worldwide, including thousands of veterans and civilians in the US. He directs a productive multidisciplinary group utilizing pharmacological, electrophysiological, histological, mass spectrometric, and transgenic techniques. Current projects in the Reddy lab are centered on elucidating the molecular pathophysiology of, and developing mechanism-based novel drug therapies for, epileptogenesis, status epilepticus, post-traumatic epilepsy, post-stroke epilepsy, and chemical neurotoxicity. He has a long standing interest in neurosteroids as novel anticonvulsants. Dr. Reddy was instrumental in discovering many preclinical models, mechanism-based treatment strategies, and novel medicines for complex brain disorders. His lab has been conducting pioneering investigations on neurosteroid interactions at synaptic and extrasynaptic GABA-A receptors. His research has been continuously funded by the NIH for over 12 years. He is the principal investigator of an NIH Cooperative Agreement U01 project focusing on novel treatments for organophosphate and chemical nerve agent intoxication. He directs a DOD project on post-traumatic epilepsy after traumatic brain injury. He teaches both medical and graduate courses on human pharmacology and pharmacodynamics and mentors many undergraduates and doctoral & postdoctoral trainees. Dr. Reddy has published over 150 papers and book-chapters (h-index 40), which are available worldwide (http://orcid.org/0000-0003-2735-9550).
- Reddy DS (2010). Neurosteroids: Endogenous role in the human brain and therapeutic potentials. Prog Brain Res 186: 113-137. http://www.ncbi.nlm.nih.gov/pubmed/21094889
- Reddy DS, Gangisetty O, and Briyal S (2010). Disease-modifying activity of progesterone in the hippocampus kindling model of epileptogenesis. Neuropharmacology 59: 573-581.
- Gangisetty O and Reddy DS (2010). Neurosteroid withdrawal regulates GABA-A receptor α4-subunit expression and seizure susceptibility by activation of PR-independent Egr3 pathway. Neuroscience 170: 865-880.
- Reddy DS and Jian K (2010). The testosterone-derived neurosteroid androstanediol is a positive allosteric modulator of GABA-A receptors. J Pharmacol Exp Therap 334:1031-1041.
- Reddy DS and Rogawski MA (2010). Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model. Epilepsy Res 89: 254-260.
- Reddy DS (2010). Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives. Expert Rev Clin Pharmacol 3(2):183-192.
- Reddy DS and Mohan A (2011). Development and persistence of limbic epileptogenesis are impaired in mice lacking progesterone receptors. J Neurosci 31: 650-658
- Reddy DS (2011). Role of anticonvulsant and antiepileptogenic neurosteroids in the pathophysiology and treatment of epilepsy. Front Endocrinol 2 (38): 1-11.
- Reddy DS, Gould J, and Gangisetty O (2012). A mouse kindling model of perimenstrual catamenial epilepsy.J Pharmacol Exp Therap 341:784-793.
- Reddy DS and Ramanathan G (2012). Finasteride inhibits the disease-modifying activity of progesterone in the hippocampus kindling model of epileptogenesis. Epilepsy & Behavior 25:92-97.
- Reddy DS (2013). Neuroendocrine aspects of catamenial epilepsy. Hormones & Behavior 63: 254–266.
- Reddy DS (2013). The pathophysiological and pharmacological basis of current drug treatment of migraine headache. Expert Rev Clin Pharmacol 6(3):271-288.
- Wu X, Gangisetty O, Carver CM and Reddy DS (2013). Estrous cycle-regulation of extrasynaptic d-containing GABA-A receptor-mediated tonic inhibition and limbic epileptogenesis. J Pharmacol Exp Therap 346(1):146-160.
- Reddy DS (2013). Role of hormones and neurosteroids in epileptogenesis. Frontiers in Cellular Neuroscience 7 (article 115) 1-20.
- Reddy DS (2013). Current pharmacotherapy of attention deficit hyperactive disorder (ADHD). Drugs of Today 49(10):647-665.
- Carver CM and Reddy DS (2013). Neurosteroid interactions with synaptic and extrasynaptic GABA-A receptors: Regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability. Psychopharmacology 230(2):151-188.
- Reddy DS and Kuruba R (2013). Experimental models of status epilepticus and neuronal injury for evaluation of therapeutic interventions. International Journal of Molecular Sciences 14:18284-18318.
- Carver CM, Wu X, Gangisetty O and Reddy DS (2014). Perimenstrual regulation of extrasynaptic d-containing GABA-A receptors mediated tonic inhibition and neurosteroid sensitivity. J Neurosci 34(43):14181-97.
- Reddy DS (2014). Neurosteroids and their role in sex-specific epilepsies. Neurobiology of Disease 72(Pt B):198-209.
- Reddy SD, Younus I, Clossen B and Reddy DS (2015). Antiseizure activity of midazolam in mice lacking delta-subunit extrasynaptic GABA-A receptors. J Pharmacol Exp Therap 353:517–528.
- Reddy SD and Reddy DS (2015). Midazolam as an anticonvulsant antidote for organophosphate intoxication: A pharmacotherapeutic appraisal. Epilepsia 56(6):813–821.
- Golub VM, Brewer J, Wu X, Kuruba R, Short J, Manchi M, Swonke M, Younus Y and Reddy DS (2015). Neurostereology protocol for unbiased quantification of neuronal injury and neurodegeneration. Front Aging Neurosci 7:196.
- Reddy DS (2016). Catamenial epilepsy: discovery of an extrasynaptic molecular mechanism for targeted therapy. Front Cell Neurosci 10(101): 1- 14.
- Younus I and Reddy DS (2016). Seizure modulating activity of the oral contraceptive ethinyl estradiol. Epilepsy Res 121:29-32.
- Carver CM and Reddy DS (2016). Neurosteroid structure-activity relationships for functional activation of extrasynaptic dGABA-A receptors in the hippocampus. J Pharmacol Exp Therap 357:188–204.
- Reddy DS and Golub VM (2016). The pharmacological basis of cannabis use for epilepsy. J Pharmacol Exp Therap 357:45–55.
- Reddy DS (2016). Clinical potential of neurosteroids for CNS disorders. Trends Pharmacol Sci 37(7): 543-561.
- Xin W, Muthuchamy M, and Reddy DS (2016). Application of atomic force microscopy protocol for measurement of membrane plasticity and extracellular interactions in single neurons in epilepsy. Front Ageing Neurosci 8(88):1-19.
- Carver CM and Reddy DS (2016). Zinc selectively inhibits the neurosteroid-sensitive, extrasynaptic d-GABA-A receptors in the hippocampus. J Neurosci 36(31):8070–8077.
- Reddy DS (2016). The neuroendocrine basis of sex differences in epilepsy. Pharmacol Biochem Behav Jul 14, 2016 [Epub ahead of print].
- Reddy DS, Bhimani A, Kuruba R, Park MJ, and Sohrabji F (2016). Prospects of modeling post-stroke epileptogenesis. J Neurosci Res July 25, 2016 [Epub ahead of print].
- Reddy DS (2016). Neurosteroids for the potential protection of humans against organophosphate toxicity. Ann New York Acad Sci July 23, 2016 [Epub ahead of print].
- Reddy DS (2016). Sex differences in the anticonvulsant neurosteroids. J Neurosci Res Aug, 2016 [Epub ahead of print].